Amicogen, Inc.
Financials
Valuation Metrics
Amicogen, Inc.'s Market Cap is ₩869B. At end of 2025 it was ₩1259B. Ranked #1356 of 2,436 in KR market (top 56%), #750 of 1,649 on KOSDAQ (top 45%), #145 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 62%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 86.91B KRW | KR#1,356/2,436 Sec#145/234 |
| Revenue | 43.44B KRW | KR#1,851/2,436 Sec#130/234 |
| Net Income | -5.20B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 213.68B KRW | KR#1,241/2,436 Sec#92/234 |
| Net Assets | 133.35B KRW | KR#1,185/2,436 Sec#93/234 |
| Employees | 223 | KR#1,006/2,436 Sec#84/234 |
| Value | ||
| P/B | 0.65x | KR#1,030/2,436 Sec#49/234 |
| P/S | 2.00x | KR#1,804/2,436 Sec#103/234 |
| FCF Yield | -32.37% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -3.90% | KR#1,709/2,436 Sec#123/234 |
| ROA | -2.43% | KR#1,732/2,436 Sec#125/234 |
| Op. Margin | -36.79% | KR#2,205/2,436 Sec#159/234 |
| Revenue Growth | 13.49% | KR#797/2,436 Sec#70/234 |
| Financial Health | ||
| Debt Ratio | 160.24% | KR#1,322/2,436 Sec#151/234 |
| Total Debt | 61.43B KRW | KR#898/2,436 Sec#63/234 |
| FCF | -28.13B KRW | KR#1,983/2,436 Sec#191/234 |
| Cash | 6.74B KRW | KR#1,872/2,436 Sec#164/234 |
| Current Ratio | 1.07x | KR#1,743/2,436 Sec#177/234 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -69.44% | KR#2,346/2,436 Sec#222/234 |
| 1M Return | -8.28% | KR#1,834/2,436 Sec#173/234 |
| From 52W High | -72.05% | KR#2,216/2,436 Sec#202/234 |
| 1Y MDD | -75.36% | KR#2,159/2,436 Sec#195/234 |
| Trading | ||
| Volume | 1,421,435 shares | KR#235/2,436 Sec#16/234 |
| Foreign Own. | 3.38% | KR#964/2,436 Sec#95/234 |
| Per Share | ||
| EPS | -79 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,879 KRW | KR#2,066/2,436 Sec#172/234 |
Company Info
Amicogen, established in 2000, is an industrial bio-specialized company that develops and produces special enzymes for pharmaceuticals, biomaterials for pharmaceuticals, and enzyme-based new biomaterials using genetic evolution technology. The company supplies CX enzyme for 7-ACA production to the global market, pursues localization of purification resins and media for antibody biopharmaceuticals, and expands its health functional food business. By securing production technology and promoting its next-generation antibiotic enzyme CDMO business, Amicogen aims to expand its global market through large-scale commercialization of biopharmaceutical materials. Amicogen is headquartered in Jinju-si, Gyeongsangnam-do.